ESR1 and breast carcinoma: Nevertheless, although estrogen-receptor negative breast cancer initially responds well to therapy, it generally becomes resistant with higher rate of recurrence compared to other subtypes of breast cancers, resulting in tumor progression and death in around 90% of patients with advanced/metastatic disease [32,33].